The Innovation Challenge P3Dx is now in full execution

Five startups selected through the Innovation Challenge P3Dx are working on decentralised test innovations that can contribute to pandemic preparedness and to broader applications across healthcare. The projects focus on innovative diagnostic solutions that are rapidly deployable, scalable, and relevant in situations where reliable diagnostics are urgently needed.

The startups are working on innovative solutions that:
✅ Support home use and small-scale testing locations
✅ Build a robust value chain — from manufacturing through to data delivery
✅ Make society more resilient to pandemic threats

The startups have taken an active role in knowledge sharing within the diagnostics-startup innovation ecosystem.

Nostics

Nostics is developing a lab-independent platform that can detect pathogens without relying on chemical reagents. The team is working on a method to rapidly assess the susceptibility of pathogens to medicines — an important step towards targeted treatment and better use of therapies.

Rapidemic

Rapidemic's technology brings the power of molecular diagnostics closer to the user — from the central laboratory to the general practitioner and potentially even to the home setting. The team is optimising its assay so that it performs better at room temperature and becomes more broadly deployable in a pandemic context.

QVQ

QVQ is building a highly diverse antibody library. The goal is to increase the likelihood that therapeutic or diagnostic antibodies can be made available more quickly when a new pandemic threat emerges.

CCassured

CCassured is developing a highly accurate molecular diagnostic solution based on CRISPR-Cas technology. The team is advancing this approach with the aim of enabling robust and scalable diagnostics at moments when fast and reliable testing is essential.

Vysens

Vysens is developing a lab-independent platform to measure immune responses quickly. The team is working on the integration of simultaneous virus detection and automated data analysis. With this, the technology can contribute to better-informed — and potentially less far-reaching — measures during outbreaks.

Meet Nostics

Meet Rapidemic

Meet QVQ

Meet CCassured

Meet Vysens

Scope of the Innovation Challenge P3Dx

1. Methods for pathogen detection

The development of biochemical, molecular, or biophysical assays that can detect pandemic and non-pandemic pathogens quickly, reliably, and affordably.

2. Platforms / Test-cassette technologies

The creation of platform technologies that allow samples to be processed and tested without laboratory infrastructure.

3. Data delivery for decentralised test innovations

Efficient delivery of test results and metadata for national use, including interoperability with existing systems and the data needed for quality control (QC).

PCP procedure

TNO set up the Innovation Challenge P3Dx through a Pre-Commercial Procurement (PCP) procedure, in order to stimulate the development of new, fast, lab-independent tests. Five of the submissions were awarded a contract. P3Dx distributed €1,000,000 across the five companies.